OSC Co-culture for Rescue IVM of Human GV Oocytes

Official title

Effect of iPSC-Derived Ovarian Support Cell Co-culture on Rescue In Vitro Maturation of Human Germinal Vesicle Oocytes: A Randomized Sibling-Oocyte Controlled Trial

Overview

This single-center randomized sibling-oocyte controlled trial evaluates whether co-culture with induced pluripotent stem cell (iPSC)-derived ovarian support cells (OSCs) improves rescue in vitro maturation (r-IVM) outcomes of surplus germinal vesicle (GV) oocytes collected during routine IVF treatment. Eligible GV oocytes from each enrolled participant are allocated within participant in a 1:1 ratio to either conventional r-IVM or r-IVM with OSC co-culture. The primary outcome is the metaphase II (MII) maturation rate after 24 hours of culture. Secondary outcomes include fertilization rate, day 3 embryo formation, good-quality day 3 embryo rate, blastocyst formation, and good-quality blastocyst rate. All embryos generated in the study are for research purposes only and will not be used for clinical embryo transfer.

Detailed description

Immature human oocytes at the germinal vesicle (GV) stage retrieved during routine IVF cycles are usually not used in standard clinical treatment. Rescue in vitro maturation (r-IVM) offers a potential strategy to increase the number of mature oocytes available for laboratory use, but maturation outcomes for GV oocytes remain limited. This study investigates whether co-culture with iPSC-derived ovarian support cells (OSCs) can improve the biological performance of r-IVM in surplus GV oocytes.

This is a single-center, randomized, sibling-oocyte controlled study conducted at the Infertility Department of Hung Vuong Hospital, Ho Chi Minh City, Vietnam. Women undergoing routine IVF who have at least two eligible GV oocytes in one retrieval cycle may participate after providing informed consent. Within each participant, eligible GV oocytes are allocated in a 1:1 ratio to either conventional r-IVM in CSCMC medium or r-IVM in CSCMC medium with iPSC-derived OSC co-culture.

Allocation is performed separately within each participant using a manual lottery-based randomization procedure. If an odd number of eligible GV oocytes is available, one oocyte is randomly excluded before allocation to preserve equal within-participant assignment. Oocytes in both groups are cultured under identical laboratory conditions; the only difference between groups is the presence of OSCs in the intervention arm. Matured oocytes are assessed after 24 hours. Oocytes reaching MII undergo ICSI, and fertilized oocytes are cultured to day 5-6 in a time-lapse system. Embryo development is evaluated using standard morphology criteria with independent assessment and time-lapse support.

The study is designed to compare biological outcomes between conventional r-IVM and OSC-supported r-IVM while minimizing between-patient confounding through within-participant allocation. The participant is treated as the clustering unit for statistical analysis.

This section is taken from the protocol's rationale, procedures, randomization logic, and outcome plan.

Interventions

• Other Conventional rescue in vitro maturation
  Standard rescue in vitro maturation of denuded germinal vesicle oocytes in CSCMC culture medium for 24 hours under routine IVF laboratory conditions.
• Other Rescue in vitro maturation with iPSC-derived ovarian support cell co-culture
  Rescue in vitro maturation of denuded germinal vesicle oocytes in CSCMC culture medium for 24 hours with co-culture using iPSC-derived ovarian support cells supplied by Dioseve Inc. and prepared according to the laboratory SOP.

Primary outcome measures

• MII maturation rate after 24 hours of culture [Time frame: 24 hours after initiation of culture]

Secondary outcome measures (5)

• Fertilization rate [Time frame: 17 to 19 hours after ICSI]
• Day 3 embryo formation rate [Time frame: Day 3 after fertilization]
• Good-quality day 3 embryo rate [Time frame: Day 3 after fertilization]
• Blastocyst formation rate [Time frame: Day 5 to Day 6 after fertilization]
• Good-quality blastocyst rate [Time frame: Day 5 to Day 6 after fertilization]

Eligibility criteria

Inclusion criteria

• Women aged 18 to 45 years.
• At least 2 GV oocytes retrieved in a single oocyte retrieval cycle.
• Voluntary informed consent from the couple to participate in the study.
• Agreement that all embryos generated from the study will be used for research purposes only and will not be transferred for clinical treatment.

Exclusion criteria

• Sperm obtained through surgical retrieval procedures, including PESA, MESA, TESE, or micro-TESE.
• Use of donor gametes, including donor oocytes or donor sperm.
• Participants with GV oocytes showing obvious morphological abnormalities, such as degeneration, severe deformation, or marked cytoplasmic abnormalities.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Single blind

Primary purpose

Basic science

Study locations

Vietnam · 1 center

• Infertility Department — Ho Chi Minh City

Identifiers

NCT: NCT07559357 · CS/HV/26/04

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗